A multi-centre, open label, single arm, 32-week treatment study in subjects with severe eosinophilic asthma not optimally controlled with current omalizumab treatment who are switched from omalizumab to mepolizumab 100mg subcutaneous (study number 204471- the OSMO study)
Phase of Trial: Phase IV
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms OSMO
- Sponsors GlaxoSmithKline
- 12 Jul 2017 Status changed from active, no longer recruiting to completed.
- 13 May 2017 This trial has been completed in Spain.
- 01 May 2017 Planned End Date changed from 9 Jun 2017 to 31 May 2017.